Simcere Pharma rose 4.81% to HK$10.67 after a low open, climbing from HK$10.17 at 09:32 BJ to an intraday HK$10.81 at 15:11 BJ, with 8.07 million shares and HK$84.7 million traded, as the deal to grant LinkHealth exclusive promotion rights for zepruxitinib in dermatology coincided with the buyback of 528,000 shares for HK$5.3634 million on November 3 and shareholder Peng Suqin adding 200,000 shares at HK$10.28; strength across Hong Kong innovative-drug names added support. Fundamentals show Q2 2026 revenue of HK$2.645 billion, up 34.67% year on year, net profit of HK$478.6 million up 45.34%, operating income of HK$601.8 million up 54.29%, a 18.09% net margin and 17.59% ROE, against a 15.17x PE and 2.53x PB. The stock sits above its MA20 of HK$10.65 but is still down 9.58% year to date, 25.8% below the 52-week high of HK$14.38 and under the MA60 of HK$11.294, leaving the move within a recovery range.